| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Biogen Inc. | Sep 24, 2026 | |
| Sell | BIOGEN INC CMN | Sep 11, 2026 | |
| Buy | BIOGEN INC. CMN | Sep 4, 2026 | |
| Sell | Biogen Inc. | Aug 18, 2026 | |
| Buy | Biogen Inc. | Jun 5, 2026 | |
| Sell | Biogen Inc. | Jun 2, 2026 | |
| Buy | BIOGEN INC CMN | May 22, 2026 | |
| Buy | Biogen Inc. | May 12, 2026 | |
| Buy | Biogen Inc. | May 11, 2026 | |
| Buy | Biogen Inc. | May 11, 2026 |
This page tracks congressional stock trading activity in Biogen Inc. (BIIB) in the Healthcare sector. Disclosed Capitol has indexed 197 disclosed congressional trades involving BIIB. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 197 disclosed congressional trades in Biogen Inc. (BIIB) — 106:84 buy-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 24, 2026 | Maria Elvira Salazar | R | Sell | $1,001 - $15,000 |
| Sep 11, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Sep 4, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Aug 18, 2026 | Kevin Hern | R | Sell | $1,001 - $15,000 |
| Jun 5, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Jun 2, 2026 | Maria Elvira Salazar | R | Sell | $15,001 - $50,000 |
| May 22, 2026 | Ro Khanna | D | Buy | $15,001 - $50,000 |
| May 12, 2026 | Maria Elvira Salazar | R | Buy | $1,001 - $15,000 |
| May 11, 2026 | Maria Elvira Salazar | R | Buy | $50,001 - $100,000 |
| May 11, 2026 | Maria Elvira Salazar | R | Buy | $1,001 - $15,000 |
Across the 197 disclosed congressional trades in Biogen Inc. (BIIB), members of Congress have reported 106 buys and 84 sells. The average 30-day alpha vs. the S&P 500 is -0.87%.
For fiscal year 2025, Biogen Inc. reported revenue of $9.89B and net income of $1.29B, per SEC filings.
Most recent reported quarter: Q1 FY2026 — revenue $2.48B, net income $319.5M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.